

SETTLEMENT AGREEMENT AND RELEASE

CA Citizen Protection Group, LLC (“CCPG”) and Genesco Inc. (“Genesco”) enter into this Settlement Agreement and Release (this “**Agreement**”). This Agreement is effective on the date on which it is fully executed by all Parties (“**Effective Date**”). CCPG and Genesco are referred to individually as a “**Party**” and collectively as the “**Parties**.” The Parties agree as follows:

1. The “**Matter**” arises out of:
 - a. A Sixty-Day Notice of Intent to Sue for alleged Violations of the Safe Drinking Water and Toxic Enforcement Act of 1986, codified under California Health & Safety Code (“**HSC**”) sections 25249.5, *et seq.* (referred to as “**Proposition 65**”), that CCPG served on Levi Strauss & Co., Burlington Stores, Inc., Burlington Merchandising Corp., Burlington Distribution Corp., Burlington Coat Factory of Texas, Inc., and Burlington Coat Factory Warehouse Corporation, dated October 01, 2024 and filed as AG No. 2024-04140 (the “**Notice**”) with respect to a product sold by Genesco.
 - b. The Notice alleges that Proposition 65 warnings are required for alleged consumer exposure to Di-n-butyl Phthalate (“**DBP**”) from use of the product. The following product manufactured, distributed and/or sold by Genesco is referred to as the “**Covered Product**” under this Agreement:

- **Levi's Flip Flops, UPC: 191605858278**

2. The Parties enter into this Agreement to fully resolve all claims, demands, and allegations regarding the Matter and for the purpose of avoiding prolonged litigation. Nothing in this Agreement shall be construed as an admission by any Party of any fact, issue of law, or violation of law, nor shall compliance with this Agreement constitute or be construed as an admission by any Party of any fact, issue of law, or violation of law including but not limited to Proposition 65. Nothing in this Agreement or any document referred to herein shall be construed as giving rise to any presumption or inference of admission or concession by the Parties as to any fault, wrongdoing, or liability. This Section 2 shall not diminish or otherwise affect the obligations, responsibilities, and duties of the Parties under this Agreement.

3. DBP Standards; Warnings.


3.1 On and after the date that is ninety (90) days after the Effective Date, Genesco shall not sell in the State of California a Covered Product which does not qualify as a Reformulated Covered Product under Section 3.3, unless such Covered Product complies with the warning requirements of Section 3.2.

3.2 On and after ninety (90) days after the Effective Date, Genesco shall provide on the Covered Product (to the extent it does not constitute a Reformulated Covered Product) a warning that complies with the requirements of Section 3.2. The warning shall be displayed on the product or product packaging of the Covered Product with such conspicuousness, as compared with other words, statements, or designs so as to render it likely to be read and understood by an ordinary individual purchasing or using the Covered Product.

Respecting the warnings defined in Sections 3.2.1 or 3.2.2, the warning must be prominently displayed on a label or labeling and must be displayed with such conspicuousness as compared with other words, statements, designs or devices on the label or labeling, as to render the warning likely to be seen, read, and understood by an ordinary individual under customary conditions of purchase or use. In no case shall the warning appear in a type size smaller than 6-point type.

3.2.1 Option 1.

For the Covered Product, the warning may state:

 **WARNING: This product can expose you to chemicals, including Di-n-butyl Phthalate (DBP), which are known to the State of California to cause birth defects or other reproductive harm. For more information, go to www.P65Warnings.ca.gov.**

3.2.2 Option 2.

For the Covered Product, the warning may state:

 **WARNING: Birth defects or other reproductive harm from exposure to Di-n-butyl Phthalate (DBP) – See www.P65Warnings.ca.gov.**

The pictogram specified in Section 3.2.1 and 3.2.2 shall be in yellow with a black exclamation mark; *provided however*, the pictogram may be in white instead of yellow if the Covered Product label or packaging does not contain the color commonly referred to as yellow.

3.2.3 Option 3.

In lieu of Option 1 or Option 2 set forth in Sections 3.2.1 and 3.2.2, the Covered Product may be labeled with any safe harbor warning authorized by regulation applicable to the covered product and chemical at issue in effect on or after the Effective Date.

3.2.4 Internet Sales. In addition to affixing the warning or alternative warning as provided for above to the Covered Product's packaging or labeling, the warning or alternative warning shall be posted on websites where Genesco offers the Covered Product for sale to consumers in California. The requirements of this subsection 3.2.4 shall be satisfied if the warning or alternative warning is put on the product display page, or a clearly marked hyperlink using the word "**WARNING**", appears on the product display that links to the warning, or by an otherwise "prominently displayed" warning provided to the purchaser prior to completing the purchase. For purposes of this subsection, the warning is not "prominently displayed" if the purchaser must search for it in the general content of the website.

3.2.5 Language Other than English. Where the label or packaging of the Covered Product used to provide a warning includes consumer information about the Covered Product in a language other than English, the warning must also be provided in that language in addition to English.

3.3 Reformulated Covered Product. A Reformulated Covered Product is one for which the concentration of DBP is less than 0.1% by weight (1,000 parts per million (ppm)) as tested by an approved laboratory and methods in compliance with Section 3.4 below. For a Covered Product

that contains (any part of the product/packaging) 0.1% by weight (1,000 ppm), or more, DBP, Genesco shall provide the warnings set forth in Section 3.2.

3.4. Formula, Testing and Quality Control Methodology.

3.4.1 For purposes of this Agreement, exposure levels shall be measured in parts per million (milligrams/kilogram or mg/kg) by generally accepted scientific standards. The testing requirements do not apply to any Covered Product for which Genesco has provided a warning as specified in Section 3.2.

3.4.2 Genesco shall not be required to engage in testing pursuant to this Agreement unless Genesco sells into California the Covered Product without a warning. All testing pursuant to this Agreement shall be performed using a laboratory method that complies with any United States Environmental Protection Agency (“USEPA”) or California Environmental Protection Agency (“CAEPA”) approved testing method.

3.4.3 Unless warnings are affixed consistent with the requirements of Section 3.2, all testing pursuant to this Agreement shall be performed by an independent third-party laboratory approved by, accredited by, or registered with the CAEPA or USEPA. Testing shall be performed prior to Genesco’s “first sale” in California of the Covered Product ordered for production after the Effective Date, and testing shall continue thereafter at least once per year for three (3) consecutive years after the Effective Date (the “**Testing Period**”), after which time, no further testing shall be required under this Agreement, unless, after the Testing Period, Genesco changes suppliers for the Covered Product, then Genesco shall test the Covered Product at least once after such change is made.

3.5 Genesco and the “Releasees” (as defined in Section 5.1 below) shall have no obligation or liability with respect to Covered Product that is sold or distributed in California prior to or after the date of this Agreement and the Notice, except as otherwise set forth in this Agreement.

4. Genesco shall pay the total settlement amount of Twenty-One Thousand Five Hundred Dollars (\$21,500) (the “**Settlement Amount**”) within fourteen (14) days of the Effective Date. Genesco shall pay the Settlement Amount and related payments by wire transfer (via account wire instructions provided by CCPG’s counsel immediately upon execution of this Agreement.)

CCPG shall be solely responsible for allocating the payment pursuant to Sections 4.1 and 4.2. As a condition to Genesco’s payment obligations arising under this Agreement, CCPG shall supply Genesco with a completed W9 form on behalf of itself or its counsel, as applicable. The Settlement Amount shall be allocated as follows:

4.1. \$700 shall be considered a “civil penalty”, of which CCPG shall remit seventy-five percent (75%) to the “Safe Drinking Water and Toxic Enforcement Fund” managed by the State of California’s Office of Environmental Health Hazard Assessment. The twenty-five percent (25%) balance shall be remitted to CCPG.

4.2 \$20,800 shall be considered reimbursement of CCPG’s attorneys’ fees and costs related to the Matter.

4.3 Except as expressly set forth in Section 4, the Parties shall bear their own costs, expenses, and attorneys' fees related to this Matter.

5. Binding Effect; Claims Covered and Released.

5.1. CCPG, on behalf of itself and its respective owners, principals, shareholders, officers, directors, employees, agents, parents, subsidiaries, successors, assigns, and legal representatives (collectively referred to as "**CCPG Releasors**") fully releases and waives any right to participate (directly or indirectly) in any litigation against (a) Genesco, and its equity owners, parents, subsidiaries, affiliates, sister and related companies, (b) its upstream suppliers and all downstream entities in the stream of commerce including but not limited to distributors, wholesalers, customers, retailers, franchisees, cooperative members, licensees, and licensors (including but not limited to its licensor Levi Strauss & Co. and its customer Burlington Stores, Inc., and all parent, subsidiary, and affiliate companies of Burlington Stores, Inc.), and (c) the employees, shareholders, officers, directors, members, managers, equity owners, insurers, attorneys, predecessors, successors, and assigns of any of the entities identified in subsections (a) and (b), above (the entities identified in subsections (a), (b) and (c), above, are collectively referred to as "**Releasees**") and fully releases the Releasees from all claims, actions, suits, demands, liabilities, damages, penalties, fees (including but not limited to attorneys' fees, investigator fees, and expert fees), costs, and expenses (collectively referred to as "**Claims**") that were asserted, or that could have been asserted, for any alleged violations of Proposition 65, or any other alleged violation of statutory or common law, arising from alleged exposures to DBP in the Covered Product.

5.2. It is possible that other claims not known to the Parties arising out of the facts alleged in the Notice and relating to the Covered Product will develop or be discovered. CCPG on behalf of itself and the CCPG Releasors, acknowledges that this Agreement is expressly intended to cover and include all such claims, including all rights of action therefore, and further acknowledges that the Claims released in Section 5 may include unknown claims, and nevertheless waives California Civil Code section 1542 as to any such unknown claims. California Civil Code section 1542 reads as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

CCPG acknowledges and understands the significance and consequences of this specific waiver of California Civil Code Section 1542.

5.3. The Parties agree that compliance with the terms of this Agreement shall constitute compliance by any Releasee with Proposition 65 regarding alleged exposures to DBP in the Covered Product.

5.4. It is the Parties' position that the commitments they have agreed to herein, and actions taken and to be taken by Genesco under this Agreement, confer a significant benefit to the general public, as set forth in California Civil Procedure Code section 1021.5 and Cal. Admin.

Code Title 11, section 3201. As such, to the extent any other private party initiates an action alleging a violation of Proposition 65 with respect to Genesco or any Releasee's failure to provide a warning concerning exposures to DBP with respect to the Covered Product they have respectively manufactured, distributed, sold, licensed, or offered for sale in California, or will manufacture, distribute, sell, or offer for sale in California; such private party action would not confer a significant benefit on the general public as to the Covered Product addressed in this Agreement, provided that Genesco is in compliance with this Agreement. This subsection 5.4 does not constitute a release by CCPG under this Agreement.

6. Resolution of Disputes.

6.1 If CCPG alleges that Genesco has failed to comply with this Agreement, prior to filing an action or motion relating to enforcement, CCPG shall first provide to Genesco thirty (30) days' advance written notice of the alleged violation(s). CCPG shall provide testing results, lot numbers, photographs of the Covered Product, and purchase receipts for the Covered Product at issue in the alleged violation, as applicable. The Parties shall meet and confer during such thirty (30) day period in an effort to reach agreement on an appropriate cure for the alleged violation without the need for litigation.

6.2 Notwithstanding the provisions of Section 3, CCPG may not issue any notice under Section 6.1 if the packaging of a Covered Product is marked or labeled with the statement "Not for Sale in California" or substantially similar language, such statement is prominently placed upon such Covered Product's label or other labeling as compared with other words or statements on the label or labeling as to render it likely to be read and understood by an ordinary individual under customary conditions of purchase or use. If Genesco mark or label the Covered Product with such a statement, Genesco shall additionally notify its customers/distributors by correspondence that the Covered Product shall not be sold in California.

6.3 In the event any litigation, arbitration, mediation, or other proceeding is initiated by any party to enforce this Agreement, the prevailing party shall be entitled to recover from the non-prevailing Party all costs, expenses, reasonable attorneys' fees, and expert witness fees, relating to or arising out of (i) such proceeding, and (ii) any post judgment or post-award proceeding including without limitation to enforce any judgment or award resulting from any such proceeding.

7. This Agreement contains the entire agreement between the Parties with regard to settlement of this Matter, and supersedes all prior or contemporaneous agreements or understandings, written or oral, with regard to the matters set forth in this Agreement. This Agreement may be amended or modified in whole or in part at any time only by an agreement in writing executed by the Parties. Notwithstanding the foregoing, Genesco shall be entitled, at its option, to modify any warning that it provides under Section 3.2 to conform with any change in the Proposition 65 warning regulations currently set forth in Title 27 of the California Code of Regulations that may be adopted after the Effective Date. CCPG shall cause this Agreement to be reported to the State of California Attorney General as required and applicable under Proposition 65 statutes, including specifically HSC § 25249.7.

8. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective owners, principals, shareholders, members, managers, officers, directors, employees, agents, successors, assigns and Releasees.

9. No inference, assumption or presumption shall be drawn, and no provision of this Agreement shall be construed against any of the Parties, based upon the fact that one of the Parties and/or one of the Parties' attorneys prepared and/or drafted all or any portion of this Agreement. It is conclusively presumed that the Parties participated equally in the preparation and drafting of this Agreement.

10. This Agreement shall be deemed to have been entered into in the State of California and governed and interpreted by the laws of the State of California, regardless of the place of incorporation, place of business, domicile of any of the Parties or physical locations of the individuals executing this Agreement at the time of execution.

11. The Parties acknowledge that they have a right to consult an attorney and they have consulted their attorneys with respect to the terms and conditions of this Agreement or by signing this Agreement hereby acknowledge they have made the decision not to consult with an attorney in this Matter. The Parties further acknowledge that they fully understand this Agreement and the effect of signing and executing this Agreement.

12. Any legal action to enforce this Agreement or related to this Matter shall be brought in either the County of Alameda or the County of Los Angeles, of the State of California.

13. This Agreement may be signed in counterparts, and each counterpart, as well as any facsimile, e-mail (.pdf), DocuSign, copy of this Agreement, or any other counterpart, shall be deemed to be an original.

14. All notices required to be given to either Party under this Agreement shall be in writing and sent to the following recipients by (a) first-class mail or (b) overnight delivery, with a courtesy copy via email, as indicated below.

For CCPG:

CA Citizen Protection Group, LLC
c/o Khansari Law Corporation
21650 Oxnard Street, Suite 1540
Woodland Hills, California 91367
Tel.: (818) 650-6444
Fax: (818) 650-6445
Email: andre@khansarilaw.com

For Genesco:

Jessalyn H. Zeigler, Esq.
Bass, Berry & Sims PLC
21 Platform Way, Ste 3500
Nashville, TN 37203
Tel.: 615-742-6289
Email: jzeigler@bassberry.com

15. Each of the individuals who executes this Agreement represents and warrants he/she has the authority to execute this document and bind the respective Parties to the terms and conditions of this Agreement, and has read, understood, and agreed to all the terms and conditions in this Agreement.

DATED: June 6, 2025

CA CITIZEN PROTECTION GROUP, LLC

By: Tal Ohana

Name: Tal Ohana

Title: Manager

DATED: June 5, 2025

GENESCO INC.

By: Scott E. Becker

Name: Scott Becker

Title: SVP, General Counsel & Corporate Secretary